Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Care Plans, Education Improve Long-term Quality of Life

June 17, 2023
By Julie M. Vose, MD, MBA
Publication
Article
OncologyONCOLOGY Vol 37, Issue 6
Volume 37
Issue 6
Pages: 233

Co-editor-in-Chief Julie M. Vose, MD, MBA, writes about the optimal ways to manage short- and long-term toxicities associated with cancer.

With 1 in 3 individuals receiving a cancer diagnosis sometime during their lifetime, we all are likely to experience cancer ourselves or to have a relative or close friend with cancer. Fortunately, there have been vast improvements in treatments and care for patients with cancer. But with those successful treatments often come short- and long-term toxicities that must be managed.

In 2006, the Institute of Medicine and the National Academies established a committee to examine the range of medical and psychosocial issues faced by cancer survivors needed to improve their health care and quality of life.1 The committee set out 10 recommendations that fit into 4 broad categories: prevention, surveillance, intervention, and coordination.1 One big part of the recommendations was that each patient who had received cancer therapy should receive a survivorship care plan written by the team providing the cancer care. These plans should be developed systematically and on evidence-based clinical practice guidelines, the committee noted. Many of these plans have been developed as a shared-care model in which specialists work collaboratively with primary care providers. This model is likely the most successful because much of the cancer survivor’s health care is provided by their primary care network.

In addition to evaluations for cancer recurrence, services are needed for cancer screenings and evaluation of secondary effects such as organ dysfunction or secondary malignancies. Educating patients on primary and secondary prevention services, such as smoking cessation or regular cancer screening tests, is an important part of cancer survivorship. Cancer survivors also should receive additional lifestyle education such as how to maintain a healthy weight or increase activity. Some vital issues that are difficult to address include the need for services from psychologists or social workers. Even though the American Disabilities Act, has offered cancer survivors some protections from discriminatory practices, there are still many cases of health-related discrimination. Survivorship is an essential part of cancer care and benefits should be available based on evidence-based medicine.

The written survivorship care plan that is done at the end of active treatment for a patient with cancer does not guarantee a smooth transition or adequate education. It is an outline or road map for the patient, family, and primary care physician to follow. It should be a short, concise document that contains relevant information but does not overwhelm the patient or family. A specialty team trained to deliver the survivorship care plan is particularly beneficial in assisting patients with the transition.

A follow-up national cancer policy forum workshop in 2017 examined the implementation of the 2006 recommendations.2 Although many of the original recommendations have been implemented, some are less universal, such as protections from health-related discriminatory practices.2 Investing in research to improve cancer survivorship also was called out in the recommendations, particularly research on mechanisms of the late effects, prevalence of the risk of late effects, and interventions to improve the quality of life of all cancer survivors, their families, and caregivers. As a community of hematologists/oncologists, we owe it to our patients to not only improve our anticancer therapies but also to decrease the short- and long-term effects of the therapies we recommend for our patients.

References

  1. Institute of Medicine and National Research Council. From Cancer Patient to Cancer Survivor: Lost in Transition. The National Academies Press; 2005.
  2. Kline RM, Arora NK, Bradley CJ, et al. Long-term survivorship care after cancer treatment - summary of a 2017 National Cancer Policy Forum workshop. J Natl Cancer Inst. 2018;110(12):1300- 1310. doi:10.1093/jnci/djy176
Download Issue PDFDownload PDF
Articles in this issue

Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma
Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma
Squamous Cell Carcinoma of the Kidney: A Large Case Series
Squamous Cell Carcinoma of the Kidney: A Large Case Series
Erdafitinib’s Road to Approval and Use in Urothelial Carcinoma
Erdafitinib’s Road to Approval and Use in Urothelial Carcinoma
Researchers Seek More Treatment Options for Gastrointestinal Cancer
Researchers Seek More Treatment Options for Gastrointestinal Cancer
Care Plans, Education Improve Long-term Quality of Life
Care Plans, Education Improve Long-term Quality of Life
Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Physical therapists may play a key role in patient care before, during, and after treatment for cancer, according to Alison Ankiewicz, PT, DPT.
Related Content
Advertisement

Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.

Late Hepatic Recurrence From Granulosa Cell Tumor: A Case Report

Prosper Akankwasa, MBBS;Jackson Kakooza, MBBS;Aisha Abdullahi Ahmed, MBBS;Catherine R. Lewis, MD, PhD
October 28th 2025
Article

Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


PET-adapted strategies enhance treatment for advanced classical Hodgkin lymphoma, optimizing outcomes through individualized escalation and de-escalation based on PET results.

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era

Wael Abdulla Moh Khair, MD
October 26th 2025
Article


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

Russ Conroy
October 24th 2025
Article

ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.


Notably, improvements in both the ESR1 mutated population and the intent-to-treat population, including ESR1 wild type, were announced, and data will be presented at an upcoming scientific meeting.

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

Neil M. Iyengar, MD
October 24th 2025
Article

Read about recent advancements in breast cancer treatment, including new therapies and survival data, showcased at the upcoming ESMO 2025 Congress.

Related Content
Advertisement

Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.

Late Hepatic Recurrence From Granulosa Cell Tumor: A Case Report

Prosper Akankwasa, MBBS;Jackson Kakooza, MBBS;Aisha Abdullahi Ahmed, MBBS;Catherine R. Lewis, MD, PhD
October 28th 2025
Article

Granulosa cell tumors exhibit late recurrence and rare hepatic metastasis, emphasizing the need for lifelong surveillance in affected patients.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


PET-adapted strategies enhance treatment for advanced classical Hodgkin lymphoma, optimizing outcomes through individualized escalation and de-escalation based on PET results.

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era

Wael Abdulla Moh Khair, MD
October 26th 2025
Article


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

Russ Conroy
October 24th 2025
Article

ESMO Congress 2025 included a variety of presentations that may change the treatment paradigm in lung cancer, breast cancer, and other types of disease.


Notably, improvements in both the ESR1 mutated population and the intent-to-treat population, including ESR1 wild type, were announced, and data will be presented at an upcoming scientific meeting.

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

Neil M. Iyengar, MD
October 24th 2025
Article

Read about recent advancements in breast cancer treatment, including new therapies and survival data, showcased at the upcoming ESMO 2025 Congress.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.